RESUMO
Previously, we discovered geldanamycin, a ligand of heat shock protein 90, effectively inhibited herpes simplex virus type 1 replication in vitro and in vivo (mouse encephalitis model). In this study, we demonstrate that geldanamycin has very strong activities against herpes simplex virus type 2 in vitro and in vivo (mouse vagina model). In mouse vagina model, administration of geldanamycin suspension to vagina after virus infection protected the infected mice from death and increased the average survival days in a dose-dependent manner. Geldanamycin also significantly reduced virus shedding from mouse vagina. All geldanamycin-treated groups were statistically significant when compared with the infected control group. The high-dose group of geldanamycin (5.72 mg kg(-1)) was better than acyclovir group (2.86 mg kg(-1)). All geldanamycin vaginal administration mock-infected groups did not show significant body weight loss. Although geldanamycin has strong antiviral activities against various DNA and RNA viruses, geldanamycin is not suitable for systemic administration because of its high toxicity. We consider that geldanamycin is a candidate of topical usage for the treatment of herpes simplex virus type infections.
Assuntos
Antivirais/administração & dosagem , Antivirais/farmacologia , Benzoquinonas/administração & dosagem , Benzoquinonas/farmacologia , Herpes Genital/tratamento farmacológico , Herpesvirus Humano 2/efeitos dos fármacos , Lactamas Macrocíclicas/administração & dosagem , Lactamas Macrocíclicas/farmacologia , Replicação Viral/efeitos dos fármacos , Administração Intravaginal , Animais , Modelos Animais de Doenças , Feminino , Herpes Genital/virologia , Herpesvirus Humano 2/fisiologia , Camundongos , Análise de Sobrevida , Resultado do Tratamento , Vagina/virologia , Eliminação de Partículas ViraisRESUMO
Currently, there is no approved antiviral drug for the infection caused by enteroviruses. A series of novel N-arylethyl isoquinoline derivatives defined with substituents on the ring A and C were designed, synthesized and evaluated in vitro for their activities against Coxsackievirus B3 (CVB3). The primary structure-activity relationship revealed that substituents on the ring A were not beneficial for the activity. Among these analogs synthesized, compound 7f bearing a methylenedioxy at the R(4) and R(5) positions afforded an anti-CVB3 activity and a reasonable selectivity index (SI=26.8); furthermore, 7f exhibited a moderate activity against enterovirus 71 (EV71) with SI value of 9.0. Thus it has been selected as an anti-enteroviral lead compound for further investigation.